US FDA approves first-in-class treatment for kidney disease
As a condition of the accelerated approval, the ongoing clinical trial must be completed to confirm that Trutakna slows kidney function decline over the long-term in patients with IgA nephropathy.
The United States Food and Drug Administration (US FDA) has approved Trutakna (atacicept-vymj), a first-in-class treatment developed by Vera Therapeutics, to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression.
As a condition of the accelerated approval, the ongoing clinical trial must be completed to confirm that the drug slows kidney function decline over the long term.
This is a summary of the original articles listed below. Always read the source articles for the full context. GhanaSummary does not create or modify the news — we summarise and link to original publishers.
